Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Should You Buy?

Key Points

• Pharming Group experienced a significant increase in trading volume, with 10,539 shares traded, marking a 41% rise from the previous day.
• Analysts have downgraded the stock's rating from "strong-buy" to "hold," with a consensus target price of $30.00.
• The company reported a positive earnings per share of $0.06 for the last quarter, surpassing analysts' expectations and generating revenue of $93.20 million.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares saw an uptick in trading volume on Monday . 10,539 shares changed hands during mid-day trading, an increase of 41% from the previous session's volume of 7,489 shares.The stock last traded at $14.63 and had previously closed at $14.27.

Analyst Ratings Changes

Several brokerages recently commented on PHAR. Zacks Research lowered Pharming Group from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 30th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Pharming Group in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $30.00.

Pharming Group Trading Up 2.5%

The company has a market cap of $1.00 billion, a P/E ratio of -112.50 and a beta of 0.04. The company has a quick ratio of 2.07, a current ratio of 2.79 and a debt-to-equity ratio of 0.38. The business has a 50-day moving average price of $13.87 and a two-hundred day moving average price of $11.23.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.16. The company had revenue of $93.20 million during the quarter, compared to the consensus estimate of $70.36 million. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%. Pharming Group has set its FY 2025 guidance at EPS. On average, analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.